# Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer

> **NCT04416490** · — · ACTIVE_NOT_RECRUITING · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 2013 (actual)

## Conditions studied

- Stage II Colon Cancer
- Stage III Colon Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04416490
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-25
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 2013 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04416490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04416490, "Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04416490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*